Our Best Shot - CHI’s Mandatory COVID-19 Vaccination Policy

CHI has instituted a mandatory vaccination policy for all in-person participants across all our events. Learn more about our health and safety protocols.

OPT Congress is now Back In-Person

OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout the drug development process. We bring together leading discovery and development scientists, CMC and regulatory experts, and technology providers, to help you optimize drug design and delivery, streamline manufacturing and regulatory issues and accelerate time to market.

Conference Programs

Add Dates to Outlook

Oligonucleotide Discovery and Delivery

Oligoncucleotide CMC and Regulatory Strategies

Short Courses
Event Highlights

Keynote Speakers Include:

Isabel Aznarez, PhD

Isabel Aznarez, PhD
Co-Founder, Vice President & Head, Biology, Stoke Therapeutics

Richard Geary, PhD

Richard Geary, PhD
Chief Development Officer and Executive Vice President, Antisense Drug Development, Ionis Pharmaceuticals, Inc.

Arthur M. Krieg

Arthur M. Krieg
Founder & CSO, Checkmate Pharmaceuticals

Arthur Levin, PhD

Arthur Levin, PhD
Executive Vice President, Research and Development, Avidity Biosciences

Michael Segel, PhD

Michael Segel, PhD
Postdoctoral Fellow, Laboratory of Dr. Feng Zhang, Broad Institute of MIT and Harvard

With Thanks to Our Executive Advisory Board

Dmitry Samarsky, PhD
CTO, Sirnaomics

Muthiah (Mano) Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals

Arthur Levin, PhD
Executive Vice President, Research and Development, Avidity Biosciences

Lubo Nechev, PhD
Vice President Process and Analytical Sciences, Alnylam Pharmaceuticals

Ekkehard Leberer, PhD
Senior Life Sciences Consultant, ELBIOCON


Email us at:


Ready to Register?

Secure your space now